Protagenic Therapeutics' Lead Candidate PT00114 Attenuated Chronic Stress Responses in a Well-Established Rodent Model Jun 30, 2026 08:30AM
Protagenic Therapeutics Engages Floyd Regulatory Strategic Consulting as Regulatory Affairs Advisor and Danforth Health as Strategic Operations Partner May 19, 2026 08:15AM
Protagenic Therapeutics names Bill Nichols Jr. as president Apr 23, 2026 08:19AM
Protagenic Therapeutics Appoints Industry Veteran Bill Nichols Jr. as President to Accelerate Advancement of First-in-Class TCAP Pathway Therapy PT00114 Apr 23, 2026 08:15AM
Protagenic completes Phytanix separation, reduces liabilities by $6.3 million Mar 17, 2026 08:04AM


Mar 17, 2026 08:00AM Protagenic Therapeutics Completes Phytanix Separation, Strengthens Balance Sheet and Repositions the Company Around PT00114
Mar 10, 2026 08:00AM Protagenic Therapeutics Upgrades from OTC Pink to OTCQB Venture Market
Dec 9, 2025 08:46AM Protagenic reports positive safety results from PT00114 phase 1 study
Dec 9, 2025 08:46AM Results from Phase 1 Multiple-Dose Study of PT00114
Nov 28, 2025 05:57AM Protagenic Therapeutics receives NASDAQ delisting notice
Nov 27, 2025 03:45AM Protagenic Therapeutics Announces Receipt of Nasdaq Non-Compliance Notice
Nov 13, 2025 08:22AM Protagenic Therapeutics completes Phase 1 dosing for PT00114 compound
Nov 13, 2025 08:22AM Protagenic Therapeutics Announces Completion of Enrollment and Dosing in Phase 1 MAD Study
Aug 22, 2025 05:25PM Protagenic Therapeutics Provides Update on Form 10-Q Filing Timeline and Nasdaq Compliance
Aug 21, 2025 08:12AM Protagenic completes first dose in PT00114 multiple-dose phase 1 trial
Aug 21, 2025 08:12AM Protagenic Therapeutics Advances PT00114 into Multiple-Dose Phase 1 Trial; Positioning for Phase 2 in Stress & Mood Disorders
Jul 30, 2025 08:31AM Protagenic Therapeutics receives Japan patent for epilepsy drug compounds
May 21, 2025 09:19AM Protagenic Therapeutics Inc. (PTIX) Receives $3.1 Million from Recent Warrant Activity
May 21, 2025 09:15AM Protagenic Therapeutics Receives $3.1 Million from Recent Warrant Activity
May 20, 2025 12:24PM SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Protagenic Therapeutics, Inc. Merger
May 19, 2025 07:46AM Protagenic Therapeutics (PTIX) and Phytanix Announce Business Combination to form Neuroactive Biopharmaceutical Company
May 19, 2025 07:43AM Protagenic Therapeutics and Phytanix Announce Business Combination to form Neuroactive Biopharmaceutical Company with Six Drug Candidates in Development including Treatments for Obesity and Metabolic
Apr 29, 2025 04:03PM Protagenic Therapeutics Inc. (PTIX) Announces 1:14 Reverse Share Split
Apr 29, 2025 04:00PM Protagenic Therapeutics to Effect 1-for-14 Reverse Stock Split
Dec 20, 2024 06:24AM Protagenic Therapeutics Inc. (PTIX) Files for 5.84M Share Offering by Selling Stockholders
Nov 5, 2024 08:14AM Protagenic Therapeutics (PTIX) Announces Closing of Private Placement for Aggregate Gross Proceeds of $1.275 Million
Nov 5, 2024 08:12AM Protagenic Therapeutics Announces Closing of Private Placement for Aggregate Gross Proceeds of $1.275 Million
Oct 29, 2024 09:30AM Protagenic Therapeutics Inc. (PTIX) Prices 1.95M Share Private Placement at $0.64/sh
Oct 29, 2024 09:27AM Protagenic Therapeutics Announces Pricing of Private Placement for Aggregate Gross Proceeds of $1.275 Million
Oct 29, 2024 09:27AM Protagenic Therapeutics Announces Pricing of Private Placement for Aggregate Gross Proceeds of $1.275 Million